Metastatic colorectal cancer (mCRC) remains a major challenge in oncology, with a five-year survival rate of only 14%, underscoring the need for innovative and effective treatments. Despite advances in surgery, chemotherapy, and targeted therapies, mCRC often remains incurable, highlighting the critical need for continued research and development in treatment modalities. In recent years, significant progress has been made in the treatment of mCRC, with the introduction of novel chemotherapeutic and targeted therapy agents.
Editorial: future frontiers in the management of metastatic colorectal cancer / Giovinazzo, Francesco; Gallo, Gaetano; Goglia, Marta; Pavone, Matteo; Coppola, Alessandro; Dell'Aquila, Emanuela. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 14:(2024). [10.3389/fonc.2024.1486653]
Editorial: future frontiers in the management of metastatic colorectal cancer
Gallo, GaetanoCo-primo
Supervision
;Goglia, MartaWriting – Original Draft Preparation
;Coppola, AlessandroMembro del Collaboration Group
;
2024
Abstract
Metastatic colorectal cancer (mCRC) remains a major challenge in oncology, with a five-year survival rate of only 14%, underscoring the need for innovative and effective treatments. Despite advances in surgery, chemotherapy, and targeted therapies, mCRC often remains incurable, highlighting the critical need for continued research and development in treatment modalities. In recent years, significant progress has been made in the treatment of mCRC, with the introduction of novel chemotherapeutic and targeted therapy agents.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giovinazzo_Editorial-future-frontiers_2024.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
272.13 kB
Formato
Adobe PDF
|
272.13 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
